Edgestream Partners L.P. Has $3.90 Million Position in Certara, Inc. (NASDAQ:CERT)

Edgestream Partners L.P. increased its position in Certara, Inc. (NASDAQ:CERT) by 140.3% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 365,708 shares of the company’s stock after buying an additional 213,549 shares during the period. Edgestream Partners L.P. owned 0.23% of Certara worth $3,895,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in CERT. Atria Investments Inc boosted its position in Certara by 21.6% during the third quarter. Atria Investments Inc now owns 19,743 shares of the company’s stock worth $231,000 after purchasing an additional 3,501 shares during the period. TimesSquare Capital Management LLC boosted its position in Certara by 3.1% during the third quarter. TimesSquare Capital Management LLC now owns 956,655 shares of the company’s stock worth $11,202,000 after purchasing an additional 29,090 shares during the period. Versor Investments LP bought a new stake in Certara during the third quarter worth approximately $162,000. Geneva Capital Management LLC boosted its position in Certara by 0.7% during the third quarter. Geneva Capital Management LLC now owns 5,510,209 shares of the company’s stock worth $64,525,000 after purchasing an additional 37,392 shares during the period. Finally, Oppenheimer Asset Management Inc. boosted its position in Certara by 6.8% during the third quarter. Oppenheimer Asset Management Inc. now owns 211,224 shares of the company’s stock worth $2,473,000 after purchasing an additional 13,500 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Stock Up 0.9 %

CERT opened at $11.73 on Friday. The business has a 50 day moving average of $12.56 and a 200-day moving average of $11.61. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of -58.65, a P/E/G ratio of 9.29 and a beta of 1.60. Certara, Inc. has a 1-year low of $9.41 and a 1-year high of $19.39.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CERT. William Blair reaffirmed a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. TD Cowen began coverage on Certara in a research report on Thursday, February 27th. They issued a “buy” rating and a $16.00 price objective for the company. Barclays increased their price objective on Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Finally, Stephens reissued an “overweight” rating and issued a $17.00 price objective on shares of Certara in a research report on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Certara has an average rating of “Moderate Buy” and an average target price of $15.83.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.